[go: up one dir, main page]

MX2010003599A - Intermediarios y metodos para la sintesis de analogos de halicondrina b. - Google Patents

Intermediarios y metodos para la sintesis de analogos de halicondrina b.

Info

Publication number
MX2010003599A
MX2010003599A MX2010003599A MX2010003599A MX2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A
Authority
MX
Mexico
Prior art keywords
halichondrin
analogs
synthesis
methods
intermediates
Prior art date
Application number
MX2010003599A
Other languages
English (en)
Inventor
Atsushi Endo
Jing Li
Charles Chase
Francis G Fang
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2010003599A publication Critical patent/MX2010003599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

Métodos para sintetizar intermediarios útiles para la síntesis de análogos de halicondrina B de describen.
MX2010003599A 2007-10-03 2008-10-03 Intermediarios y metodos para la sintesis de analogos de halicondrina b. MX2010003599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99762507P 2007-10-03 2007-10-03
PCT/US2008/078762 WO2009046308A1 (en) 2007-10-03 2008-10-03 Intermediates and methods for the synthesis of halichondrin b analogs

Publications (1)

Publication Number Publication Date
MX2010003599A true MX2010003599A (es) 2010-09-10

Family

ID=40019255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003599A MX2010003599A (es) 2007-10-03 2008-10-03 Intermediarios y metodos para la sintesis de analogos de halicondrina b.

Country Status (11)

Country Link
US (6) US8093410B2 (es)
EP (2) EP2578576B9 (es)
JP (1) JP5735277B2 (es)
CN (3) CN101883763B (es)
BR (1) BRPI0817909B1 (es)
CA (1) CA2701534C (es)
IL (1) IL204791A (es)
MX (1) MX2010003599A (es)
RU (1) RU2489437C2 (es)
SG (1) SG10201811715YA (es)
WO (1) WO2009046308A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682878B2 (ja) 1989-11-27 1997-11-26 上村工業株式会社 シールド付き電気めっき装置
AU762998B2 (en) 1998-06-17 2003-07-10 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
JP5735277B2 (ja) 2007-10-03 2015-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成のための中間体および方法
BRPI0911269A2 (pt) 2008-04-04 2015-09-29 Eisai R&D Man Co Ltd análogos de halicondrina b
DE102009012660A1 (de) * 2009-03-13 2010-09-16 H.C. Starck Clevios Gmbh Polymerbeschichtungen mit verbesserter Temperaturstabilität
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
CN102803254B (zh) * 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
CN102225921B (zh) * 2011-04-26 2013-04-24 中国人民解放军第二军医大学 一种环戊烷聚酮类化合物simplextone A及其用途
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2014087230A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
WO2014208774A1 (en) 2013-06-26 2014-12-31 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások
AU2015267099B2 (en) 2014-05-28 2020-08-27 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
WO2016038624A1 (en) * 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN107849057B (zh) 2015-05-07 2020-11-10 卫材R&D管理有限公司 用于合成软海绵素大环内酯的大环化反应及中间体和其他片段
JP6786610B2 (ja) * 2016-02-12 2020-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンの合成における中間体および関連する合成方法
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
ES2952680T3 (es) 2016-04-28 2023-11-03 Eisai R&D Man Co Ltd Eribulina para inhibir el crecimiento tumoral
CN114805322B (zh) * 2016-06-30 2025-05-30 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
BR112019007145A2 (pt) 2016-10-14 2019-07-02 Eisai R&D Man Co Ltd combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
RS63755B1 (sr) 2017-04-05 2022-12-30 Harvard College Makrociklično jedinjenje i njegova upotreba
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
JP7574232B2 (ja) 2019-06-21 2024-10-28 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ ホモプロパルギルアルコールを調製するための化学酵素的プロセス
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2027890C3 (de) * 1970-06-06 1979-02-01 Kali Chemie Ag 8-AIkoxy oder -Benzyloxy-3-methyl-lO- methylen-2,9-dioxatricyclo-(43,l,03,7 )-decan-4-one und 8-AIkoxy oder 8-Benzyloxy-3,10-dimethyl-2,9dioxatricyclo- (43,1,O" )-decan-4-one
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US4086245A (en) * 1976-12-09 1978-04-25 The Upjohn Company Antibiotics 7-O-alkylnogarols
SU722912A1 (ru) * 1978-03-06 1980-03-25 Уфимский Нефтяной Институт Способ получени 5-метил/-4оксо3,6,8-триоксабицикло/ (3,2,1)-октана
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (es) 1992-09-09 1995-09-01 Hoechst Ag
AU4255697A (en) 1996-09-06 1998-03-26 Eli Lilly And Company Catalytic selective sulfonylation process
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
AU762998B2 (en) * 1998-06-17 2003-07-10 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
DE10106647A1 (de) 2001-02-12 2002-08-22 Univ Hannover Ratjadon-Derivate zum Hemmen des Zellwachstums
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
CN108997267A (zh) * 2004-06-03 2018-12-14 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
WO2007039342A1 (en) 2005-09-26 2007-04-12 Symrise Gmbh & Co. Kg Intramolecular prins reaction and catalysts suitable therefor
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
WO2009014105A1 (ja) 2007-07-20 2009-01-29 Yamada Apiculture Center, Inc. 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
JP5735277B2 (ja) * 2007-10-03 2015-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成のための中間体および方法
RU2010118063A (ru) * 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения
BRPI0911269A2 (pt) 2008-04-04 2015-09-29 Eisai R&D Man Co Ltd análogos de halicondrina b
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
CN102803254B (zh) * 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN107849057B (zh) 2015-05-07 2020-11-10 卫材R&D管理有限公司 用于合成软海绵素大环内酯的大环化反应及中间体和其他片段
JP6786610B2 (ja) 2016-02-12 2020-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンの合成における中間体および関連する合成方法
CN114805322B (zh) 2016-06-30 2025-05-30 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
CN101883763B (zh) 2016-04-20
WO2009046308A1 (en) 2009-04-09
CN108948039B (zh) 2021-12-31
CN104311571B (zh) 2019-07-02
EP2200992A1 (en) 2010-06-30
US8987479B2 (en) 2015-03-24
JP5735277B2 (ja) 2015-06-17
US10214539B2 (en) 2019-02-26
CA2701534C (en) 2017-02-21
US8093410B2 (en) 2012-01-10
SG10201811715YA (en) 2019-02-27
RU2010117520A (ru) 2011-11-10
US20090198074A1 (en) 2009-08-06
BRPI0817909A2 (pt) 2015-04-07
EP2578576B9 (en) 2016-09-14
IL204791A (en) 2017-06-29
EP2200992B1 (en) 2014-02-26
US20190263826A1 (en) 2019-08-29
CN108948039A (zh) 2018-12-07
EP2578576A1 (en) 2013-04-10
BRPI0817909B1 (pt) 2022-06-21
CA2701534A1 (en) 2009-04-09
US10717743B2 (en) 2020-07-21
US9604993B2 (en) 2017-03-28
US20180037588A1 (en) 2018-02-08
RU2489437C2 (ru) 2013-08-10
EP2578576B1 (en) 2016-03-23
IL204791A0 (en) 2010-11-30
US9802953B2 (en) 2017-10-31
US20160214992A1 (en) 2016-07-28
US20120095242A1 (en) 2012-04-19
US20150225415A1 (en) 2015-08-13
CN101883763A (zh) 2010-11-10
JP2010540658A (ja) 2010-12-24
CN104311571A (zh) 2015-01-28

Similar Documents

Publication Publication Date Title
MX2010003599A (es) Intermediarios y metodos para la sintesis de analogos de halicondrina b.
IL201852A0 (en) Process for the synthesis of ramelteon and its intermediates
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
MY155424A (en) Processes for the preparation of aminosulfone compounds
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
MY163339A (en) A method of producing ingenol-3-angelate
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
WO2010068282A3 (en) Compositions and methods for synthesis of hydrogen fuel
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
AP2291A (en) Production of synthesis gas.
TWI374886B (en) Processes for preparing intermediates of pemetrexed
MX2008011666A (es) Sintesis de compuestos que modulan la actividad de la trombopoyetina.
ZA201000394B (en) Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
TW200800986A (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
TW200728310A (en) Process for the preparation of ferri-succinylcasein
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
AU2009235634A8 (en) Substituted sulfonamide derivatives
WO2010028004A3 (en) Substituted berbines and processes for their synthesis
MX2010003056A (es) Polimorfos de valomaciclovir.